Zobrazeno 1 - 10
of 183
pro vyhledávání: '"J van der Weide"'
Autor:
DA Collier, Annette M. Hartmann, A Putkonen, PF Sullivan, Dan Rujescu, H Stefansson, MC OʼDonovan, AF Pardiña, E Repo-Tiihonen, J Tiihonen, D Cohen, GG M Breen, Munir Pirmohamed, E Silva, T Hallikainen, J. van der Weide, JL Kennedy, E Sigurdsson, O Imgimarsson, JT Walters, Ina Giegling, M Rietschel, Bettina Konte, S Legge, JP Bogers, K. van der Weide
Publikováno v:
Pharmacopsychiatry.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5b349ad3755f2c013e0cb9adde3e2c0
https://doi.org/10.1055/s-0039-3403016
https://doi.org/10.1055/s-0039-3403016
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Anu Putkonen, Ina Giegling, D. A. Collier, Jan P.A.M. Bogers, Michael Conlon O'Donovan, Emil L. Sigurdsson, Jari Tiihonen, James L. Kennedy, Annette M. Hartmann, Dan Rujescu, Munir Pirmohamed, Dan Cohen, Tero Hallikainen, Oddur Ingimarsson, Eila Repo-Tiihonen, Marcella Rietschel, Patrick Sullivan, Sophie E. Legge, Bettina Konte, James T.R. Walters, Edward Silva, Hreinn Stefansson, K. van der Weide, Gerome Breen, Antonio F. Pardiñas, J. van der Weide
Publikováno v:
European Neuropsychopharmacology. 29:S1320-S1321
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2780b06257d0bad3920ac3cbc1cdb2ec
https://doi.org/10.1016/j.euroneuro.2018.08.466
https://doi.org/10.1016/j.euroneuro.2018.08.466
Publikováno v:
Acta neuropsychiatrica. 15(2)
Background:Identification of schizophrenia, a common neuropsychiatric disorder, is based on clinical examination. An easily measurable peripheral marker, which may enable a more rapid and more accurate diagnosis, is not available. A possible candidat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8942768da1f2d7fae03c5d2a240f70f2
https://pubmed.ncbi.nlm.nih.gov/26984797
https://pubmed.ncbi.nlm.nih.gov/26984797
Autor:
Edward Silva, Jan P.A.M. Bogers, Munir Pirmohamed, Engilbert Sigurdsson, Daniel J. Cohen, Sophie E. Legge, Bettina Konte, Eila Repo-Tiihonen, Oddur Ingimarsson, Ina Giegling, D. A. Collier, Dan Rujescu, Anu Putkonen, Marcella Rietschel, Patrick Sullivan, Michael Conlon O'Donovan, Tero Hallikainen, James L. Kennedy, Annette M. Hartmann, Gerome Breen, J. van der Weide, Hreinn Stefansson, K. van der Weide, Jari Tiihonen
Publikováno v:
European Neuropsychopharmacology. 29:S939
Background The atypical antipsychotic drug clozapine is the only effective drug for treatment-resistant schizophrenia, but also bears the risk of inducing severe adverse drug responses like neutropenia and agranulocytosis. Agranulocytosis and neutrop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::564901e9ac89b1b025fbe66f53b849f1
https://doi.org/10.1016/j.euroneuro.2017.08.282
https://doi.org/10.1016/j.euroneuro.2017.08.282
Autor:
Henk-Jan Guchelaar, Tom Schalekamp, A. de Boer, V.H.M. Deneer, Bob Wilffert, L. Grandia, J. van der Weide, Jesse J. Swen, A.H. Maitland-van der Zee, Marga Nijenhuis, Hans Mulder, Gerard A. Rongen, R.H.N. van Schaik, Daan J Touw
Publikováno v:
Clinical Pharmacology & Therapeutics, 89(5), 662-673. Nature Publishing Group
Clinical Pharmacology & Therapeutics, 89(5), 662-673. Wiley-Blackwell
Clinical Pharmacology and Therapeutics, 89, 662-73
Clinical Pharmacology and Therapeutics, 89, 5, pp. 662-73
Clinical Pharmacology & Therapeutics, 89(5), 662-673. Wiley-Blackwell
Clinical Pharmacology and Therapeutics, 89, 662-73
Clinical Pharmacology and Therapeutics, 89, 5, pp. 662-73
Item does not contain fulltext Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c733bb56cbfc3963328f30cca7f48191
https://hdl.handle.net/2066/96193
https://hdl.handle.net/2066/96193
Publikováno v:
The Pharmacogenomics Journal. 11:359-367
Polymorphisms in genes coding for drug metabolizing enzymes, such as the cytochrome P450 enzymes CYP2C19 and CYP2D6, can lead to therapy failure and side effects. In earlier studies, the novel variant CYP2C19*17 increased metabolism of several CYP2C1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c5c996aaba9ae3a1d4ed3d7ed8359a
https://doi.org/10.1038/tpj.2010.39
https://doi.org/10.1038/tpj.2010.39
Autor:
Toine C. G. Egberts, Olaf H. Klungel, Daan J Touw, Ingeborg Wilting, L. Grandia, Jean M. H. Conemans, A. L. de Goede, Henk-Jan Guchelaar, V.H.M. Deneer, A. de Boer, Richard P. Koopmans, Hanna Mulder, J. van der Weide, Bob Wilffert, J.J. Swen
Publikováno v:
Clinical Pharmacology & Therapeutics, 83(5), 781-787. Nature Publishing Group
Despite initial enthusiasm, 1-3 the use of pharmacogenetics has remained limited to investigation in only a few clinical fields such as oncology and psychiatry. 4-8 The main reason is the paucity of scientific evidence to show that pharmacogenetic te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f532d45e22fb57f4a73e27de4a53aa
https://doi.org/10.1038/sj.clpt.6100507
https://doi.org/10.1038/sj.clpt.6100507